idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Thema Corona

Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instanz:
Teilen: 
23.01.2023 11:01

Disarming pathogens: New drug candidates to combat chronic infections

Dr. Andreas Fischer Presse und Kommunikation
Helmholtz-Zentrum für Infektionsforschung

    Saarbrücken researchers use bacterial communication as a target for new drugs

    The pathogen Pseudomonas aeruginosa is the cause of a large number of serious infections and places a particular burden on immunocompromised patients. The increasing spread of antimicrobial resistance makes it even more difficult to combat the dreaded hospital pathogen. A research team led by Dr Martin Empting of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has now discovered a new class of active compounds that disrupt the bacterium's chemical communication pathways. This not only reduces the pathogen's disease-causing properties, but also simultaneously enhances the effectiveness of antibiotics. The researchers published their findings in the journal Advanced Science. HIPS is a site of the Helmholtz Centre for Infection Research (HZI) in collaboration with Saarland University.

    Although bacteria are among the simplest life forms on our planet, in the course of evolution they have developed ways to communicate efficiently with each other. Unlike humans, their communication is not mediated with words but with chemical signals. This interaction also plays a fundamental role in infection processes of pathogenic bacteria in humans. For example, bacteria communicate to their swarm when it is time to produce substances that counteract the human immune system. Interfering with these communication pathways is a promising starting point for the development of new therapies.

    However, the team around Dr Martin Empting, head of the Group Antiviral and Antivirulence Drugs at HIPS, did not focus on the communication messengers themselves, but on their receptors - i.e. the parts of the bacterium that are responsible for signal processing. In this specific case, the researchers targeted the receptor PqsR. When this receptor is activated, inflammation-promoting substances and biofilms are formed, in which P. aeruginosa is largely protected from antibiotics. The drug class now described was chemically designed and optimized by the researchers so that it can attack its target PqsR as efficiently as possible. This was based on structural data obtained by X-ray crystallography.

    "Since we always have a potential application in humans as a goal when developing new active substances, we had to achieve not only excellent efficacy but also good pharmacological properties and minimize undesirable side effects," says Martin Empting. He further explains, "This was not always easy, as even small changes to the molecule often have a big impact on its properties, but we can be very satisfied with our result." In further laboratory experiments, the scientists were able to show that the optimized substances reliably prevent the formation of the pro-inflammatory molecule pyocyanin in a large number of clinical isolates of P. aeruginosa. Furthermore, they were able to show that the new active ingredient is capable of impairing biofilm formation and can even further enhance the effect of the antibiotic tobramycin. Finally, the researchers were able to transfer the promising properties of their active substance to a mouse model. Here, the combined administration of tobramycin and the new PqsR inhibitor was able to combat the P. aeruginosa infection significantly better than either substance alone.

    The authors see great potential in the new compound class for future application in humans. However, before the substance can be tested in humans, complex preclinical safety studies and development processes still have to be completed. Martin Empting gives the following assessment: "We see the potential for our compounds to be used therapeutically in patients with chronic lung diseases such as cystic fibrosis or bronchiectasis and associated P. aeruginosa infections in a few years' time."

    This press release is also available on our website: https://www.helmholtz-hzi.de/en/news-events/news/view/article/complete/pathogene....

    Helmholtz Institute for Pharmaceutical Research Saarland:
    HIPS in Saarbrücken was founded in 2009 as a site of the Helmholtz Centre for Infection Research in collaboration with Saarland University. Researchers here are looking in particular for new active ingredients against infectious diseases, optimizing them for use in humans and investigating how they can best be transported to their site of action in the human body. http://www.helmholtz-hips.de

    Helmholtz Centre for Infection Research:
    Scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig and its other sites in Germany are engaged in the study of bacterial and viral infections and the body’s defence mechanisms. They have a profound expertise in natural compound research and its exploitation as a valuable source for novel anti-infectives. As member of the Helmholtz Association and the German Center for Infection Research (DZIF) the HZI performs translational research laying the ground for the development of new treatments and vaccines against infectious diseases. http://www.helmholtz-hzi.de/en

    Contact for the media:
    Dr Yannic Nonnenmacher
    PR Manager HIPS
    +49 681 98806-4500
    yannic.nonnenmacher@helmholtz-hips.de


    Originalpublikation:

    Hamed MH, Abdelsamie AS, Rox K, Schütz C, Kany AM, Röhrig T, Schmelz S, Blankenfeldt W, Arce-Rodriguez A, Borrero-de- Acuña JM, Jahn D, Rademacher J, Ringshausen FC, Cramer N, Tümmler B, Hirsch AKH, Hartmann RW & Empting M: Towards Translation of PqsR Inverse Agonists: From in vitro Efficacy Optimization to in vivo Proof-of-Principle. Advanced Science, 2023, DOI: 10.1002/advs.202204443


    Bilder

    Treatment of chronic infections caused by Pseudomonas aeruginosa (green rods) using quorum sensing inhibitors (QSI, shown in blue circle).
    Treatment of chronic infections caused by Pseudomonas aeruginosa (green rods) using quorum sensing i ...

    HIPS/Hamed


    Merkmale dieser Pressemitteilung:
    Journalisten, Wirtschaftsvertreter, Wissenschaftler
    Biologie, Chemie, Medizin
    überregional
    Forschungsergebnisse
    Englisch


     

    Treatment of chronic infections caused by Pseudomonas aeruginosa (green rods) using quorum sensing inhibitors (QSI, shown in blue circle).


    Zum Download

    x

    Hilfe

    Die Suche / Erweiterte Suche im idw-Archiv
    Verknüpfungen

    Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.

    Klammern

    Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).

    Wortgruppen

    Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.

    Auswahlkriterien

    Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).

    Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).